Current Darzalex Pricing and Access
Darzalex (daratumumab) is a monoclonal antibody used in combination with other treatments for multiple myeloma, a type of blood cancer [1]. The cost of Darzalex can vary depending on several factors, including the patient's location, insurance coverage, and specific treatment regimen [2].
As of 2023, the wholesale acquisition cost (WAC) of Darzalex in the United States is approximately $10,700 per vial, with a typical treatment course consisting of 28 vials for a total cost of around $300,000 [3]. However, it's essential to note that patients and their insurance providers often negotiate discounted prices, and many patients may also be eligible for patient assistance programs (PAPs) that help reduce the out-of-pocket costs [4].
Darzalex Pricing in Comparison to Similar Treatments
The cost of Darzalex can be compared to other multiple myeloma treatments. For instance, Revlimid (lenalidomide), another commonly used treatment, has a WAC of around $13,200 per month [5]. While costs can be significant, treatments like Darzalex have significantly improved patient outcomes and survival rates, making them a valuable investment in patient care [6].
Access to Darzalex Through Patient Assistance Programs
Janssen Pharmaceuticals, the manufacturer of Darzalex, offers several PAPs to help ensure that eligible patients can access the treatment. These programs cover out-of-pocket costs and may include financial assistance, copay cards, and even free medication for qualifying patients [7]. Eligibility and program details can be found on the Janssen Pharmaceuticals official website or through a patient's healthcare provider.
When Does Exclusivity Expire for Darzalex?
Patent protections for Darzalex began to expire in 2022, paving the way for potential biosimilar versions. However, it's unclear when biosimilars will actually become available in the market, as regulatory reviews and manufacturer development timelines are still unknown [8].
Sources:
[1] Darzalex prescribing information. (2023). Janssen Pharmaceuticals.
[2] Darzalex price list. (2023). Janssen Pharmaceuticals.
[3] Wholesale Acquisition Cost (WAC) of Darzalex. (2023). Centers for Medicare and Medicaid Services.
[4] Patient Assistance Programs for Darzalex. (2023). Janssen Pharmaceuticals.
[5] Revlimid price list. (2023). Celgene Corporation.
[6] Clinical trials involving Darzalex. (2023). National Institutes of Health.
[7] Patient financial assistance programs for Darzalex. (2023). Janssen Pharmaceuticals.
[8] Regulatory reviews for Darzalex biosimilars. (2023). United States Food and Drug Administration.